Prognostic and clinicopathological significance of systemic immune-inflammation index in upper tract urothelial carcinoma: a meta-analysis of 3911 patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High systemic immune-inflammation index (SII) predicts worse survival and adverse pathology in upper tract urothelial carcinoma (UTUC) patients. This meta-analysis highlights SII as a significant prognostic factor for UTUC outcomes.
Area Of Science
- Oncology
- Immunology
- Urology
Background
- The systemic immune-inflammation index (SII) is an emerging prognostic biomarker in various cancers.
- Upper tract urothelial carcinoma (UTUC) outcomes require improved predictive indicators.
Purpose Of The Study
- To evaluate the prognostic value of pre-treatment SII in UTUC patients.
- To investigate the association between SII and clinical-pathological features in UTUC.
Main Methods
- A systematic review and meta-analysis of published studies was conducted.
- Data from PubMed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, and VIP databases were analyzed.
- Survival outcomes and pathological features were assessed using hazard ratios (HR) and odds ratios (OR).
Main Results
- Six studies with 3911 UTUC patients were included.
- Elevated pre-treatment SII was associated with poorer overall survival (HR=1.87), cancer-specific survival (HR=2.70), and recurrence-free survival (HR=1.52).
- Higher SII correlated with lymphovascular invasion (OR=0.83), advanced pT stage (OR=1.82), and positive pN stage (OR=3.27).
Conclusions
- Pre-treatment SII is an independent predictor of unfavorable survival outcomes in UTUC.
- Elevated SII is linked to adverse pathological features in UTUC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.